Introduction: Hyponatremia predicts adverse prognosis in patients with heart failure in particular with reduced ejection fraction. In contrast, it has recently been reported that hyponatremia on admission is not a predictor of postdischarge mortality in patients with heart failure with preserved ejection fraction. We investigated the prognostic impact of hyponatremia at discharge in patients with heart failure with preserved ejection fraction and its clinical characteristics. Methods and results: The Japanese Heart Failure Syndrome with Preserved Ejection Fraction (JASPER) registry is a nationwide, observational, prospective registration of consecutive Japanese patients hospitalised with heart failure with preserved ejection fraction and left ventricular ejection fraction of 50% or greater. Five hundred consecutive patients were enrolled in this analysis. We divided the patients into two groups based on their sodium serum levels at discharge: hyponatremia group (sodium <135 mEq/L, n=50, 10.0%) and control group (sodium ⩾135 mEq/L, n=450, 90.0%). This present analysis had two primary endpoints: all-cause death and all-cause death or rehospitalisation for heart failure. At discharge, the hyponatremia group had lower systolic blood pressure (110.0 mmHg vs. 114.5 mmHg, P=0.014) and higher levels of urea nitrogen (31.9 mg/dL vs. 24.2 mg/dL, P=0.032). In the Kaplan-Meier analysis, more patients in the hyponatremia group reached the primary endpoints than those in the control group (log rank <0.01, respectively). In the Cox proportional hazard analysis, hyponatremia at discharge was a predictor of the two endpoints (all-cause death, hazard ratio 2.708, 95% confidence interval 1.557-4.708, P<0.001; all-cause death or rehospitalisation for heart failure, hazard ratio 1.829, 95% confidence interval 1.203-2.780, P=0.005). Conclusions: Hyponatremia at discharge is associated with adverse prognosis in hospitalised patients with heart failure with preserved ejection fraction.
Introduction
Heart failure (HF) is a major cause of death among the elderly in many countries and has become a significant public health issue. 1, 2 In particular, heart failure with preserved ejection fraction (HFpEF) is an increasing public health problem. [3] [4] [5] [6] Hyponatremia, which is usually defined as sodium serum levels less than 135 mEq/L, is a well-known predictor of adverse prognosis in hospitalised patients with HF with reduced ejection fraction (HFrEF). [7] [8] [9] [10] In hospitalised patients with HFrEF, hyponatremia on admission is associated with higher in-hospital and post-discharge mortality. 8, 9 In contrast, Park et al. have recently reported that hyponatremia on admission was not a predictor of post-discharge mortality in hospitalised patients with HFpEF. 11 In addition, they suggested that hyponatremia at discharge seemed to be more important for the prognosis. 11 Thus, the aim of this present analysis was to clarify the prognostic impact of hyponatremia on HFpEF patients and its clinical characteristics, using data from the Japanese Heart Failure Syndrome with Preserved Ejection Fraction (JASPER) registry, a HFpEF-specific nationwide cohort study in hospitalised patients for acute decompensated HF. 12 
Methods

Patient recruitment
The JASPER registry 12 is a multicentre, observational, prospective cohort that includes consecutive patients aged 20 years and older who require hospitalisation after being diagnosed as having acute HF according to the Framingham criteria 13 by at least two experienced cardiologists. Preserved left ventricular (LV) systolic function was defined as left ventricular ejection fraction (LVEF) of 50% or greater by the modified Simpson method or LV fractional shortening of 25% or greater by echocardiography. Patients with acute coronary syndrome, receiving haemodialysis or with a history of heart transplantation were excluded. The patients' demographic data, including comorbid conditions, medications, initial treatments, laboratory and echocardiographic data, and length of hospital stay were obtained. With respect to medications, the dose was not registered in the present study. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 ml/min/1.73 cm 2 . 14 Follow-up was performed at discharge, as well as at 12 and 24 months after discharge by coordinators or investigators at each site, as follows: direct contact with patients or their physicians at the hospital or outpatient clinic; telephone interview of patients or, if deceased, family members; or by mail. 12 The causes of death and rehospitalisation for HF as endpoints were judged by experienced cardiologists at each site.
In the current study, because patient information was anonymised and de-identified prior to the analyses, written informed consent was not obtained from each patient, and opt-out methods weres adopted as previously reported. 12, 15 However, the study was publicised by posting a summary of the protocol on the National Cerebral and Cardiovascular Center website, where a notice clearly informed patients of their right to refuse enrollment. These procedures for informed consent and enrollment were in accordance with detailed regulations regarding informed consent described in the guidelines, and this study, including the procedure for enrollment, was approved by the institutional review board of each site and registered under the Japanese UMIN Clinical Trials Registration (UMIN000010601). 12 The patient flow chart of the present analysis is shown in Figure 1 . The exclusion criteria were as follows: patients who died during the first hospitalisation; patients with unknown serum levels of sodium; and/or patients who received tolvaptan, an arginine vasopressin (AVP) V 2 receptor antagonist. Of 535 patients enrolled in the JASPER registry, 35 patients met the exclusion criteria. Finally, 500 patients were enrolled in this present analysis. We divided these patients into two groups based on sodium serum levels at discharge: the hyponatremia group (sodium <135 mEq/L, n=50, 10.0%) and the control group (sodium ⩾135 mEq/L, n=450, 90.0%). We compared the patients' demographic data, laboratory and echocardiographic data, in-hospital treatment, length of hospital stay, and prognosis after discharge between the groups. During the post-discharge follow-up period, 71 patients (14.2%) were missed. This present analysis had two primary endpoints: (a) all-cause death and (b) all-cause death or rehospitalisation for HF.
Statistical analysis
Normality was confirmed using the Shapiro-Wilk test in each group. Parametric variables were presented as mean ± standard deviation, non-parametric variables were presented as a median (interquartile range), and categorical variables were expressed as numbers and percentages. Parametric variables were compared using Student's t test, non-parametric variables were compared using the Mann-Whitney U test, and the chi-square test was used for comparisons of categorical variables. The Kaplan-Meier analysis was used for presenting all-cause death and the composite endpoint of all-cause death or rehospitalisation for HF, and the log-rank test was used for initial comparisons. The proportional hazards assumption for the model was checked by examining log minus log-transformed data. The curves helped in identifying the non-proportionality patterns in hazard function such as convergence (the difference in risk between the two groups decreases with time), divergence or crossing of the curves. We conducted subgroup analyses to assess the potential heterogeneity of associations between hyponatremia and (a) all-cause death and (b) all-cause death or rehospitalisation for HF. Interactions between hyponatremia and clinically relevant variables were estimated by the Cox proportional hazards analysis. The subgroups were based on possible confounding factors including the presence or absence of medication, and the median value of several parameters. A P value of less than 0.05 was considered statistically significant for all comparisons. All analyses were performed using a statistical software package (SPSS version 25, IBM, Armonk, NY, USA).
Results
Of the 500 enrolled patients, 44 (8.8%) patients had serum sodium levels less than 135 mEq/L on admission, 14 (2.8%) of whom had sustained hyponatremia, while 30 (6.0%) had corrected serum sodium levels at discharge ( Figure 1 ). On the other hand, 36 (7.2%) patients newly developed hyponatremia during hospitalisation (Figure 1 ). At discharge ( Figure 1 ), 50 (10.0%) patients had hyponatremia. During the post-discharge follow-up period of a median of 733 (interquartile range 568-815) days, there were 75 all-cause deaths and 116 rehospitalisations for HF. First, we confirmed the prognostic impact of sodium serum levels on admission and at discharge using the Kaplan-Meier analysis (Figures 2 and 3 ). The existence of hyponatremia on admission was not significantly associated with all-cause death (Figure 2 (a), log rank 0.091) and the composite endpoint of all-cause death or rehospitalisation for HF ( Figure 3 (a), log rank 0.457). On the other hand, the hyponatremia group at discharge showed higher all-cause death and reached the composite endpoint more often than the control group. (allcause death, Figure 2 (b), log rank <0.001; all-cause death or rehospitalisation for HF, Figure 3 (b), log rank 0.004). Next, we compared patients' characteristics and treatment between the control and hyponatremia groups at discharge (Table 1 ). There were no statistical differences in age, sex, body weight and body weight loss between the two groups, while the hyponatremia group demonstrated a higher prevalence of New York Heart Association functional class III or IV (13.0% vs. 5.1%, P=0.043), and lower systolic blood pressure at discharge (110.0 mmHg vs. 114.5 mmHg, P=0.014) compared with the control group. The prevalence of prior HF admission was more common (52.1% vs. 34.7%, P=0.018) in the hyponatremia group. Both groups obtained similar initial treatments. Echocardiographic parameters, including LVEF, LV outflow tract velocity time integral, inferior vena cava diameter, and tricuspid regurgitation pressure gradient were comparable between the two groups.
Laboratory data are summarised in Table 2 . The median sodium serum levels were 138.0 mEq/L on admission and 132.0 mEq/L at discharge in the hyponatremia group, which were significantly lower than those in the control group (P<0.001, respectively). There was no significant difference in levels of B-type natriuretic peptide (BNP), potassium and creatinine between the two groups both on admission and at discharge. At discharge, haemoglobin levels were lower (10.7 g/dL vs. 11.4 g/dL, P=0.032), blood urea nitrogen (BUN), BUN/creatinine ratio, and C-reactive protein were higher in the hyponatremia group compared with the control group (P<0.05, respectively).
In the Cox proportional hazard analysis (Tables 3 and 4 ), hyponatremia at discharge was associated with all-cause death (hazard ratio (HR) 2.708, 95% confidence interval (CI) 1.557-4.708, P<0.001) and the composite endpoint of all-cause death or rehospitalisation for HF (HR 1.829, 95% CI 1.203-2.780, P=0.005). The subgroup analysis (Tables 3  and 4 ) presented the association between hyponatremia and (a) all-cause death and (b) all-cause death or rehospitalisation for HF in each subgroup considering possibly confounding variables. To predict all-cause death, and the composite endpoint of all-cause death or rehospitalisation for HF, there were no interactions between hyponatremia and clinically important variables including the use of angiotensin converting enzyme inhibitors/angiotensin II receptor blockers, spironolactone and loop diuretics.
Discussion
In this HFpEF-specific registry, we revealed the characteristics and prognosis of hospitalised HFpEF patients who presented with hyponatremia. Hospitalised HFpEF patients with hyponatremia at discharge showed more severe symptoms, lower systolic blood pressure, higher levels of BUN and BUN/creatinine ratio, lower levels of haemoglobin, and had a higher prevalence of prior HF admission. Hyponatremia at discharge was associated with higher allcause death and the composite endpoint of all-cause death or rehospitalisation for HF.
The underlying mechanisms of hyponatremia in acute decompensated HF have been reported as follows: activation of the renin-angiotensin-aldosterone system (RAAS); stimulation of the sympathetic nervous system (SNS); and baroreceptor-mediated non-osmotic AVP release due to arterial underfilling caused by decreased cardiac output. 16, 17 Serum sodium levels are reported to be slightly lower in patients with HFrEF than those with HFpEF, 18 but the prevalence of hyponatremia (sodium <135 mEq/L) is equivalent in HFrEF and HFpEF patients. 10, 19 In addition, side effects of HF medication such as diuretics may worsen hyponatremia. 17 In the present analysis, decreased systolic blood pressure and increased levels of BUN and BUN/creatinine ratio supported the pathophysiology of arterial underfilling, activated RAAS and SNS, and AVP release. 20, 21 In hospitalised patients with HFpEF, hyponatremia on admission has been reported to predict in-hospital death, but not the prognosis after discharge. 9, 11 In the present study, concordant with reports by Park et al., 11 hyponatremia on admission was not associated with post-discharge prognosis. There have been several reports discussing a change in sodium status during hospitalisation in patients with HF. [22] [23] [24] HF patients who develop hyponatremia during hospitalisation have neurohormonal activation. 23 Therefore, the prognostic difference between hyponatremia on admission and at discharge in this analysis might probably be due to the change in RAAS/SNS/AVP activation.
Of the patients with hyponatremia on admission, 68.2% had corrected serum sodium levels during hospitalisation, suggesting that their neurohormonal activation improved. Conversely, 7.9% of patients without hyponatremia on admission developed hyponatremia during hospitalisation along with exacerbation of neurohormonal factors. Even though RAAS, SNS and AVP are important compensatory mechanisms in critical conditions including blood loss and low cardiac output, sustained activation of these systems has potential adverse effects on prognosis in HF patients by increased afterload and myocardial oxygen consumption, and induced cardiomyocyte remodeling. [25] [26] [27] [28] As hyponatremia occurs secondary to RAAS/SNS/AVP activation and the side effects of treatment, hyponatremia at discharge is a useful marker for predicting post-discharge prognosis rather than a primary risk factor. 16, 17 Regarding haemoglobin levels at discharge, there was a number of anaemic participants in the JASPER registry. Unfortunately, the cause of anaemia had not been registered. Generally, patients with HFpEF have a higher prevalence of true anaemia relative to those with HFrEF. 29 However, the lower haemoglobin levels seen in the hyponatremia group probably represented the false anaemia due to renal water retention in the setting of the development of hyponatremia. 16, 17 In this present analysis, patients in the hyponatremia group showed more severe symptoms, lower systolic blood pressure, had a higher prevalence of prior HF admission and higher serum levels of BUN at discharge. These results suggest that HFpEF patients with hyponatremia have severe or advanced HF. 30, 31 The length of hospital stay was relatively longer 18, 32, 33 and the prevalence of hyponatremia was lower 10, 11 in the JASPER registry than in other registries previously reported from other regions. This phenomenon might be due to geographical variations including patients' characteristics, background therapy and healthcare systems. 34, 35 There was no difference in BNP plasma levels, which is one of the strongest predictors of death in patients with HF 36 between the two groups. However, BNP is mainly secreted by LV stretch and diastolic wall stress, and is generally lower in patients with HFpEF than in those with HFrEF. [37] [38] [39] The discrepancy can be explained from the structural features that LV diastolic diameter and LV wall thickness were comparable between the two groups. 40 These results suggest that the reliability of BNP plasma levels in HFpEF patients with hyponatremia is relatively lower than that in patients with HFrEF. To date, the treatment methods of HFpEF patients with hyponatremia have remained unclear. Considering the increased neurohormonal activation described above, neurohormonal antagonists are likely to show a desirable prognostic impact as in the case of patients with HFrEF. 1, 2 However, angiotensin-converting enzyme inhibitors, 41 angiotensin receptor blockers, 42, 43 and β-blockers 44 have failed to improve clinical outcomes in previous studies of patients with HFpEF, whereas a significant effect is evident in patients with HFrEF. 1, 2 Diuretics may relieve symptoms, 45 but at the same time, potentially worsen neurohormonal activation and lower serum sodium levels. 17 At the moment, mineralocorticoid receptor antagonists 46 and angiotensin receptor blockers 43 are expected to reduce hospitalisation for HF. Although AVP V 2 receptor antagonists did not improve the prognosis in patients with HFrEF, 47, 48 they have also been reported to reduce hospitalisation in patients with HFpEF. 49 
Study strengths and limitations
There were several strengths to the present analysis. First, we analysed observational and prospective data from multicentres in Japan. HF was restricted to acute HFpEF requiring hospitalisation and the diagnosis was made by at least two experienced cardiologists. 12 Second, sodium serum levels both on admission and at discharge were available in the JASPER registry. 12 We were able to compare the prognostic impact of hyponatremia at two different times. On the other hand, there were some limitations in this present analysis. The general limitations of the JASPER registry were described in the previous article. 12 Regarding sodium, the change in serum levels after discharge could not be determined. Although we conducted the subgroup analysis on the basis of the presence or absence of medications (e.g. diuretics), the dose of medications was not registered. In addition, as diuretics, the prescription of spironolactone, loop diuretics and tolvaptan, except for thiazide, were registered. As the number of participants enrolled in the JASPER registry was relatively small, there was a possibility that the impact of hyponatremia on admission could not be detected. In addition, our results for causal relationship and the mechanism of hyponatremia and prognosis could not be explained because this was only an observational study.
Conclusion
Hyponatremia at discharge is associated with adverse prognosis in hospitalised patients with HFpEF.
